In 2019, the biopharma industry continued to be faced with challenges related to drug pricing, but also made major achievements, including advances with novel modalities such as potentially curative gene therapies. Against this backdrop, biopharma dealmaking did not disappoint, with plenty of mergers and partnerships signed.
Total merger and acquisition (M&A) volume in 2019 reached 310 transactions, a steady increase over the 269 deals done in 2018, according to Informa's Medtrack and Strategic Transactions. Deals included those in the biopharma industry, as well as consumer and over-the-counter (OTC) drugs, drug delivery technologies, contract research, manufacturing and clinical trial services, but excluded devices, diagnostics, research tools, animal health and insurance. A total of US$238 billion was spent on 2019 M&As, a 46% increase over the $163 billion aggregate in 2018. Transaction volume and value fluctuated quarter to quarter, but the beginning of 2019 featured several outliers that propelled the totals in Q1 and Q2 to nearly $100 billion each ( Fig. 1a ).
worth more than $1 billion and 47% of the value ( Supplementary Fig. 1 ). Pfizer paid $11.4 billion for Array BioPharma and its targeted therapies including the combination Braftovi (encorafenib)/Mektovi (binimetinib) for BRAF-V600E or BRAF-V600K mutant unresectable or metastatic melanoma. Merck & Co. similarly did a big deal around targeted therapies, buying ArQule and its lead oral Bruton's tyrosine kinase inhibitor ARQ531 for $2.7 billion. And Eli Lilly did its largest acquisition to date, acquiring Loxo Oncology for $8 billion and gaining its tumour-agnostic product Vitrakvi (larotrectinib) for solid tumours with a neurotrophic receptor tyrosine kinase gene fusion.
Acquisitions in gene therapy and other types of regenerative medicine have now become commonplace among the biopharma industry's largest M&As, and 2019 was no different. Including the CAR-Ts that came with Bristol's Celgene buy, there were two other gene therapy-focused deals in the top 10: Roche's $4.8 billion acquisition of Spark (finally cleared by both US and UK regulators 10 months after the deal Most (81%) of the $238 billion in M&A value was attributed to the top 10 acquisitions (Table 1 ). The two largest deals of the year were about diversifying into new therapy areas and easing the blow from anticipated patent expirations on blockbuster products. Generics of Celgene's top seller Revlimid (lenalidomide) are expected in 2022, and that was probably one of the drivers behind Bristol-Myers Squibb's $74 billion acquisition of Celgene at the start of 2019.
Other key assets gained include the immunoinflammatory compound ozanimod and the pipeline of CAR-T therapies Celgene obtained in its 2018 acquisition of Juno Therapeutics. AbbVie is facing biosimilar competition to Humira (adalimumab) starting in 2023, and its $63 billion takeover of Allergan will supply a strong base of additional revenue, including the company's medical aesthetics business (notably Botox), as well as ophthalmology, women's health and gastrointestinal drugs.
In addition to Celgene, there were three other major takeovers to build up pharma's capabilities in oncology, which represented 26% of the volume of deals From The analysT's CouCh naTure reviews | DrUg DiScovery announcement), and Astellas' purchase of Audentes Therapeutics for $3 billion. Also notable in 2019 was the creation of Viatris, the top generics company worldwide based on consolidated revenue, through the merger of Mylan and Pfizer's Upjohn business unit. The new company brings together Mylan's complex generics and biosimilars with Upjohn's off-patent branded and generic products, and is forecast to have $19-20 billion in 2020 pro forma revenues.
Although 2019 was an exceptional year for M&As, biopharma partnering did not reach the level of robust activity in 2018. According to Medtrack and Strategic Transactions, 2,780 alliances occurred in 2019, a 7% decrease from 2018's record number of 3,003 partnerships (Fig. 1b) . The transactions include the same industries as those reviewed for M&A, as well as diagnostics, medical devices and enabling technologies. The year started strongly with nearly 800 partnerships totalling close to $50 billion in Q1, followed by a steady decline in deal volume for the remaining quarters. However, despite a nearly 50% drop in deal values in Q2, the rebound in the second half of the year propelled the total announced values for the year to just over $161 billion, up from $131.1 billion in 2018. The top 10 partnerships of 2019 ( Supplementary Table 1 ) had a combined value of $52.6 billion (compared with $34.7 billion in 2018), representing more than one-third of the annual total.
Amgen's acquisition of global rights to Otezla (apremilast) from Celgene for Nurix for $2.3 billion. The agreement with existing partner Galapagos gives Gilead access to six clinical compounds, including GLPG1690 (in phase III trials for idiopathic pulmonary fibrosis) and more than 20 preclinical programmes, as well as Galapagos' drug discovery platform. The Nurix collaboration, which involved an $45 million upfront payment along with potential milestones totalling $2.3 billion, provides Gilead with the option to license drug candidates directed to up to five targets developed from Nurix's targeted protein degradation technology.
Once again, announced milestones continued to dominate over upfront payments in deal structures in most of the top valued deals, minimizing financial risk during the development process. Equity stakes as part of upfront consideration and shared R&D expenditure also remain significant components of partnerships.
As in past years, oncology-related deals represented the lion's share by volume, garnering 28% of the total, just as they had in 2018. Central nervous system disorders were in second place at 12%, followed by infectious disease and diagnostics, with 8% and 7%, respectively (Fig. 1c ). This ranking order is relatively unchanged from 2018.
Most deals were signed with at least one asset at the research/discovery phase (including deals for which the phase was undisclosed) followed by preclinical, continuing the same pattern as in previous years (see Supplementary Fig. 2 ). One shift, however, was in the number of transactions involving products already on the market, which exceeded those deals with phase II products (221 and 205, respectively). Q1 2019 showed high average values for phase II assets mostly due to outlier transactions during that time period by AstraZeneca/Daiichi Sankyo ($6.9 billion) and GlaxoSmithKline/Merck KGaA ($4.2 billion), respectively. The completion of Amgen's acquisition of Otezla drove up the Q4 values, but overall, average deal values remained high across the board in 2019.
